Global $111+ Billion Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis 2024-2034 - Rapid Growth in Exon-Skipping Therapies Reflects Precision Medical Interventions Fueled by R&D
March 11, 2024 14:03 ET
|
Research and Markets
Dublin, March 11, 2024 (GLOBE NEWSWIRE) -- The "Global Duchenne Muscular Dystrophy Drugs Market by Drug Type, by Distribution Channel, and By Region" report has been added to ...
Rare Neuromuscular Diseases(NMD) Emerging Pipeline Therapeutics Analysis Report 2022 with Focus on ALS, MG, DMD, SMA, DN & CIDP
December 07, 2022 06:48 ET
|
Research and Markets
Dublin, Dec. 07, 2022 (GLOBE NEWSWIRE) -- The "Emerging Therapeutics for Rare Neuromuscular Diseases: Pipeline Analysis" report has been added to ResearchAndMarkets.com's offering. Biologics...
Scott+Scott, Attorneys at Law, LLP Announces Investigation of Sarepta Therapeutics, Inc.
March 28, 2017 11:41 ET
|
Scott + Scott, Attorneys at Law, LLP
NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national shareholder and consumer rights litigation firm, announces an investigation into Sarepta...
Race to Yes Underscores Evidence Presented at FDA Advisory Committee Meeting for Duchenne Muscular Dystrophy Drug Eteplirsen
April 27, 2016 13:38 ET
|
The Race to Yes
Organization Urges FDA to Use the Evidence Presented by Dozens of Scientists, Physicians, Patients and Advocates as Required by 2012 FDASIA Act for Conditional Approval Experts Remind Duchenne...